Search results for "hormones"

showing 10 items of 1169 documents

Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk fa…

2013

Abstract STUDY QUESTION: What alters cardiovascular and metabolic risk factors with aging in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Lipid parameters, mainly low-density lipoprotein (LDL) cholesterol, increase with aging, but not in women who attain ovulatory cycles. WHAT IS KNOWN ALREADY: Cardiovascular and metabolic parameters tend to increase with aging, but this has not been shown in a prospective longitudinal study in women with PCOS. Correlates of these changes have not been identified. STUDY DESIGN: A prospective cohort of 118 hyperandrogenic women with PCOS who were followed from the age of 20-25 years at 5 year intervals for 20 years. PARTICIPANTS/MATERIALS, SE…

AdultBlood GlucoseOvulationmedicine.medical_specialtyWaistSettore MED/09 - Medicina Internamedia_common.quotation_subjectmedicine.medical_treatmentBiologyBody Mass IndexSettore MED/13 - EndocrinologiaRisk FactorsInternal medicineTotal cholesterolPrevalencemedicineHumansInsulinLongitudinal StudiesGonadal Steroid HormonesOvulationmedia_commonMetabolic SyndromeCompeting interestsInsulinPolycystic ovary syndrome (PCOS)RehabilitationMetabolic riskAge Factorsnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseLipidsSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyReproductive MedicineCardiovascular DiseasesPCOS Cardiovascular risk aging hyperandrogenism ovarian function lipid alterationsFemalelipids (amino acids peptides and proteins)Waist CircumferenceMetabolic syndromePolycystic Ovary Syndrome
researchProduct

Endothelial dysfunction in PCOS. role of obesity and adipose hormones

2006

PURPOSE: Polycystic ovary syndrome (PCOS) is an extremely prevalent disorder in which elevated blood markers of cardiovascular risk and altered endothelial function have been found. This study was designed to determine if abnormal carotid intima-media thickness (IMT) and brachial flow-mediated dilation (FMD) in young women with PCOS may be explained by insulin resistance and elevated adipocytokines. METHODS: A prospective study in 50 young women with PCOS (age: 25.2 +/- 1 years; body mass index [BMI]: 28.7 +/- 0.8) and 50 matched ovulatory controls (age: 25.1 +/- 0.7 years; BMI: 28.5 +/- 0.5) was performed. Carotid IMT, brachial FMD, and blood for fasting glucose, insulin, leptin, adiponect…

AdultBlood Glucosemedicine.medical_specialtyinsulinBrachial ArteryendotheliumPeptide Hormonesmedicine.medical_treatmentAdipokineleptinBody Mass IndexInsulin resistanceInternal medicineAdipocytesmedicineBody Fat DistributionHumansResistinObesityProspective Studiescardiovascular diseasesEndothelial dysfunctionAdiponectinadiponectinbusiness.industryInsulinLeptinpcosEndothelial dysfunction in PCOS: role of obesity and adipose hormones.nutritional and metabolic diseasesGeneral Medicinemedicine.diseasePolycystic ovaryVasodilationCarotid ArteriesEndocrinologyCase-Control Studiespcos; endothelium; insulin; adiponectin; leptincardiovascular systemCytokinesFemaleResistinEndothelium VascularInsulin ResistanceTunica IntimaTunica MediabusinessBlood Flow VelocityPolycystic Ovary Syndrome
researchProduct

Hormone therapy is associated with better body composition and adipokine/glucose profiles

2012

Objective: The aim of this study was to evaluate the possibility of preventing the metabolic health consequences of postmenopausal hypogonadism with the use of long-term hormone therapy (HT). Methods: We used a monozygotic co-twin control design including 10 twin pairs (aged 56-62 y) discordant for HT (duration of HT, 2-10 y). In addition, 14 premenopausal women (aged 29-35 y) who did not use HT were studied to evaluate the differences in metabolic health between the premenopausal and postmenopausal states. Body composition was determined, and waist-to-hip ratio was used as an estimate for fat distribution. Serum sex steroids, sex hormone-binding globulin, and serum lipid and glucose profil…

AdultBlood Glucosenaisetmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentkehon koostumusCo twin controlAdipose tissueAdipokineCarbohydrate metabolismAdipokinesSex Hormone-Binding GlobulinInternal medicineLeukocytesmedicineHumansRNA MessengerGonadal Steroid HormonesMuscle SkeletalChemokine CCL2kehonkoostumusMetabolic healthkaksostutkimusWaist-Hip Ratiobusiness.industryEstrogen Replacement TherapyadipokoinesObstetrics and Gynecologyta3141Twin studyTwins MonozygoticMiddle Agedadipokiinitmedicine.diseaseLipidsPostmenopauseMenopauseEndocrinologyAdipose TissuePremenopauseEstrogenCase-Control StudiesBody CompositionFemaleHormone therapyInsulin ResistancebusinessMenopause
researchProduct

A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy

2007

Mutations in the Angiogenin gene (ANG) linked to 14q11.2 have been recently discovered to be associated with Amyotrophic Lateral Sclerosis (ALS) in Irish and Scottish populations. In our study we investigated the role of ANG gene in ALS patients from southern Italy. We found a novel mutation in the signal peptide of the ANG gene in a sporadic patient with ALS (SALS). The molecular analysis of the ANG gene also demonstrated an allelic association with the rs11701 single nucleotide polymorphism (SNP) in familial ALS (FALS) but not in SALS patients. Our finding supports the evidence that the ANG gene is involved in ALS.

AdultGenetic MarkersMaleSignal peptideAngiogenin geneAngiogeninGenetic LinkageDNA Mutational AnalysisSingle-nucleotide polymorphismGene mutationBiologyPolymorphism Single NucleotidemedicineHumansSNPGenetic Predisposition to DiseaseGenetic TestingAlleleAmyotrophic lateral sclerosisGeneGenetics (clinical)AgedChromosomes Human Pair 14Motor NeuronsGeneticsAmyotrophic Lateral SclerosisChromosome MappingRibonuclease PancreaticMiddle Agedmedicine.diseaseAssociation studyAmino Acid SubstitutionItalyNeurologyCytoprotectionMutationNerve DegenerationPediatrics Perinatology and Child Healthcardiovascular systemCancer researchFemaleNeurology (clinical)ALShormones hormone substitutes and hormone antagonistsNeuromuscular Disorders
researchProduct

Livebirth after uterus transplantation.

2015

Uterus transplantation is the first available treatment for absolute uterine infertility, which is caused by absence of the uterus or the presence of a non-functional uterus. Eleven human uterus transplantation attempts have been done worldwide but no livebirth has yet been reported.In 2013, a 35-year-old woman with congenital absence of the uterus (Rokitansky syndrome) underwent transplantation of the uterus in Sahlgrenska University Hospital, Gothenburg, Sweden. The uterus was donated from a living, 61-year-old, two-parous woman. In-vitro fertilisation treatment of the recipient and her partner had been done before transplantation, from which 11 embryos were cryopreserved.The recipient an…

AdultGraft RejectionMalemedicine.medical_specialty46 XX Disorders of Sex Developmentmedicine.medical_treatmentUterusFertilization in VitroTacrolimusCongenital AbnormalitiesGynecologic Surgical ProceduresPre-EclampsiaAdrenal Cortex HormonesPregnancyUterus transplantationAzathioprinemedicineLiving DonorsHumansCaesarean sectionMullerian DuctsSwedenPregnancybusiness.industryObstetricsCesarean SectionUterusInfant NewbornGestational ageImmunosuppressionGeneral Medicinemedicine.diseaseEmbryo TransferSurgeryTransplantationmedicine.anatomical_structureApgar ScoreApgar scoreFemalebusinessLive BirthImmunosuppressive AgentsInfant PrematureLancet (London, England)
researchProduct

Complications in Immunosuppressive Therapy of Liver Transplant Recipients

2011

BACKGROUND: In liver transplantation (LT), modern immunosuppressive protocol is focused on early corticosteroid (CS) weaning. The aim of the study was to investigate all early transplant-related complications using Clavien grading system, in order to identify a significant relation in two homogenous groups of consecutive liver transplanted patients, only different for steroid avoidance in immunosuppressive regimen. MATERIALS AND METHODS: One group was treated with a tacrolimus-based CS-free immunosuppressive protocol, the other one underwent tacrolimus plus low dose CS therapy. The preoperative continuous variables analyzed were age, gender, model for end-stage liver disease (MELD) score, a…

AdultGraft RejectionMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicatecomplicationLiver transplantationGastroenterologyTacrolimusYoung AdultLiver diseasePostoperative ComplicationsAdrenal Cortex HormonesInternal medicinemedicineHumansAgedRetrospective Studiesimmunosuppressionbusiness.industryIncidenceLiver DiseasesIncidence (epidemiology)ImmunosuppressionMiddle Agedmedicine.diseaseTacrolimusLiver TransplantationSurgerySurvival RateRegimenCorticosteroidDrug Therapy CombinationFemaleSurgeryrejectionComplicationbusinessImmunosuppressive AgentsJournal of Surgical Research
researchProduct

Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double-Blinded Placebo-Controlled Trial

2007

Early steroid withdrawal after liver transplantation (LT) is desirable in order to reduce steroid side effects. Between February 2000 and August 2004, 110 patients after LT were included in this prospective, randomized, double-blind, placebo-controlled trial. Randomization was performed before LT. In all patients, tacrolimus was used without induction therapy. All patients received methylprednisolon for 14 days, thereafter a double-blinded medication containing either placebo (n = 56) or methylprednisolon (n = 54) for 6 months, which was completely stopped thereafter. End points were patient and graft survival, acute and chronic rejection, and incidence of steroid side effects during the fi…

AdultGraft RejectionMalemedicine.medical_specialtyTime FactorsRandomizationmedicine.drug_classmedicine.medical_treatmentPlacebo-controlled studyLiver transplantationPlaceboMethylprednisoloneGastroenterologyTacrolimuslaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansImmunology and AllergyPharmacology (medical)Antibacterial agentTransplantationbusiness.industryMiddle AgedTacrolimusLiver TransplantationSurgeryCorticosteroidFemaleSafetybusinessImmunosuppressive AgentsFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency

1990

Intravenous corticotropin-releasing factor (CRF) and adrenocorticotropin hormone (ACTH) were administered in patients with adult onset 21-hydroxylase deficiency to compare their diagnostic capability as well as to investigate hypothalamic-pituitary-adrenal function in this disorder. Responses of 17-hydroxyprogesterone, which were markedly elevated compared with controls, were identical with CRF and ACTH. However, intravenous ACTH resulted in higher androstenedione levels in comparison to CRF. Adrenocorticotropin hormone also resulted in decreased cortisol responses, confirming a defect in steroidogenesis, a finding that was not evident with CRF. Plasma ACTH responses to CRF were similar in …

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentCorticotropin-Releasing HormoneLate onsetPeptide hormoneDecreased cortisolAdrenocorticotropic HormoneInternal medicineAdrenal GlandsHydroxyprogesteronesmedicineHumansTestosteroneIn patientAndrostenedioneAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneAndrostenedione21-HydroxylaseObstetrics and GynecologyDiagnostic testEndocrinologyReproductive MedicinePituitary GlandSteroid Hydroxylasesbiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women

1990

Eighteen hyperandrogenic, hirsute women received ovine corticotropin-releasing factor (CRF; 1 microgram/kg) as well as a dexamethasone (DEX) suppression test. Nine of the 18 hirsute women exhibited increased DEX sensitivity. Plasma adrenocorticotropic hormone (ACTH) responses after ovine CRF were significantly lower in the DEX-sensitive subgroup, but serum androstenedione was higher. Baseline serum androgen levels could not predict DEX responses. A significant negative correlation existed between the suppression of androgens after DEX and the increase in ACTH after ovine CRF. The suppression of androgen correlated with the ratio of the increase in androgen to the increase in ACTH after ovin…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentCorticotropin-Releasing Hormonemedicine.drug_classMicrogramAdrenocorticotropic hormoneDexamethasoneAdrenocorticotropic HormoneInternal medicinepolycyclic compoundsAnimalsHumansMedicineAndrostenedioneDexamethasonehirsutismSheepbusiness.industryHyperandrogenismObstetrics and GynecologyAndrogen AntagonistsAndrogenmedicine.diseasePathophysiologyEndocrinologyReproductive MedicineAndrogensFemalebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugFertility and Sterility
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct